Sodyum valproat kullanımına bağlı izole trombositopeni

Yıl 2019, Cilt: 1 Sayı: 4, 110 - 112, 22.09.2019

Mehmet Hamdi Örüm

https://doi.org/10.38053/agtd.559649

Cited By: 1

Öz

Sodyum valproate şizoaffektif
bozukluk, bipolar bozukluk ve epilepsy tedavisinde kullanılan ilaçlardan
biridir. Tremor, halsizlik, Reye benzeri sendrom, karaciğer yetmezliği,
pankreatit bu ilacın yan etkilerinden bazılarıdır. Trombositopeni, sodyum
valproatın bir başka ciddi yan etkisidir. Burada, sodyum valproat ile ilişkili
izole trombositopenili bir olguyu literatür bilgileri ışığında ele aldık.

Anahtar Kelimeler

Sodyum valproat, trombositopeni, yan etki, bipolar bozukluk

Sodium valproate-induced isolated thrombocytopenia

Öz

Sodium valproate is one of the
medications used in the treatment of schizoaffective disorder, bipolar
disorder, and epilepsy. Tremor, drowsiness, Reye-like syndrome, hepatic
failure, thrombocytopenia, pancreatitis are the most frequent side effects of
this medication. Thrombocytopenia is another serious side effect of sodium
valproate. Here, we report the case of a patient with thrombocytopenia
associated with sodium valproate.

Anahtar Kelimeler

Sodium valproate, thrombocytopenia, side effect, bipolar disorder

Kaynakça

• 1. Orum MH, Kalenderoglu A, Egilmez OB, Ozen ME, Kapici Y. Hyponatremia associated with repeated use of sodium valproate. Psychiatry and Behavioral Sciences 2018;8:93-4.
• 2. Schmidt D. Adverse effects of Valproate. Epilepsia 1984;25:44-9.
• 3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed.; Author: Washington, DC, 2013.
• 4. Kose S, Akin E, Cetin M. Adverse drug reactions and causality: The Turkish version of Naranjo Adverse Drug Reactions Probability Scale. Psychiatry and Clinical Psychopharmacology 2017; 27: 205-6.
• 5. Kurahashi H, Takami A, Murotani K, Numoto S, Okumura A. Decreased platelet count in children with epilepsy treated with valproate and its relationship to the immature platelet fraction. Int J Hematol 2018; 107: 105-11.
• 6. Buoli M, Serati M, Botturi A, Altamura AC. The risk of thrombocytopenia during valproic acid therapy: A critical summary of available clinical data. Drugs R D 2018; 18: 1-5.
• 7. Nasreddine W, Beydoun A. Valproate-induced thrombocytopenia: a prospective monotherapy study. Epilepsia 2008; 49: 438-45.
• 8. Facciolà G, Avenoso A, Scordo MG, Madia AG, Ventimiglia A, Perucca E, et al. Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders. Ther Drug Monit 1999; 21: 341-5.
• 9. May RB, Sunder TR. Hematologic manifestations of long-term valproate therapy. Epilepsia 1993; 34: 1098–101.
• 10. Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Saf 1994; 10: 93-102.
• 11. Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry 2002; 63: 384-90.
• 12. Ozen ME, Orum MH, Kalenderoglu A. Difficult patient in psychiatry practice: A case-control study. Adıyaman Üni Sağlık Bilimleri Derg 2018; 4: 1064-73.